Revenue from Contract with Customer (Policies)

3 Months Ended

Sep. 30, 2023

Revenue from Contract with Customer [Abstract]

Revenue

REVENUES

The Company's revenues by segment and by payers/customer groups for the three and nine months ended September 30, 2023, and 2022, were as follows:

	For the Three Months Ended September 30, 2023								For the Three Months Ended September 30, 2022
	North America		Europe		Other		Total		North America		Europe		Other		Total
Payer/Customer
Dx
Clients	24	%	—	%	—	%	24	%	23	%	—	%	—	%	23	%
Patients	9	%	—	%	—	%	9	%	8	%	—	%	—	%	8	%
Medicare and Medicaid	8	%	—	%	—	%	8	%	8	%	—	%	—	%	8	%
Third party	36	%	—	%	—	%	36	%	38	%	—	%	—	%	38	%
Total Dx revenues by payer	77	%	—	%	—	%	77	%	77	%	—	%	—	%	77	%
BLS
Pharmaceutical, biotechnology and medical device companies	10	%	9	%	4	%	23	%	10	%	9	%	4	%	23	%
Total revenues	87	%	9	%	4	%	100	%	87	%	9	%	4	%	100	%

	For the Nine Months Ended September 30, 2023								For the Nine Months Ended September 30, 2022
	North America		Europe		Other		Total		North America		Europe		Other		Total
Payer/Customer
Dx
Clients	24	%	—	%	—	%	24	%	22	%	—	%	—	%	22	%
Patients	9	%	—	%	—	%	9	%	8	%	—	%	—	%	8	%
Medicare and Medicaid	8	%	—	%	—	%	8	%	8	%	—	%	—	%	8	%
Third party	36	%	—	%	—	%	36	%	39	%	—	%	—	%	39	%
Total Dx revenues by payer	77	%	—	%	—	%	77	%	77	%	—	%	—	%	77	%
BLS
Pharmaceutical, biotechnology and medical device companies	10	%	9	%	4	%	23	%	10	%	9	%	4	%	23	%
Total revenues	87	%	9	%	4	%	100	%	87	%	9	%	4	%	100	%

Revenues in the U.S. were $2,550.6 (83.4%) and $2,392.4 (83.5%) for the three months ended September 30, 2023, and 2022, respectively, and for the nine months ended September 30, 2023, and 2022, were $7,645.0 (83.8%) and $7,454.0 (83.4%), respectively.

Accounts Receivable, Unbilled Services and Unearned Revenue

The following table provides information about accounts receivable, unbilled services, and unearned revenue from contracts with customers:

	September 30, 2023		December 31, 2022
Dx accounts receivable	$	1,160.0	$	1,046.9
BLS accounts receivable	829.8		769.3
Less BLS allowance for doubtful accounts	(32.8)		(30.7)
Accounts receivable	$	1,957.0	$	1,785.5
Gross unbilled services	$	116.9	$	222.3
Less reserve for unbilled services	(8.9)		(10.5)
Unbilled services	$	108.0	$	211.8
Unearned revenue	$	360.8	$	310.6

Revenues recognized during the period that were included in the unearned revenue balance at the beginning of the period were $6.3 and $9.3 for the three months ended September 30, 2023 and 2022, respectively, and $79.1 and $65.9 for the nine months ended September 30, 2023, and 2022, respectively.

Credit Loss Rollforward

The Company estimates future expected losses on accounts receivable, unbilled services and notes receivable over the remaining collection period of the instrument. The rollforward for the allowance for credit losses for the nine months ended September 30, 2023, is as follows:

	Accounts Receivable		Unbilled Services		Note and Other Receivables		Total
Balance as of December 31, 2022	$	30.7	$	10.5	$	0.7	$	41.9
Plus, credit loss expense	6.2		—		—		6.2
Less, write offs	(4.1)		(1.6)		—		(5.7)
Balance as of September 30, 2023	$	32.8	$	8.9	$	0.7	$	42.4

The credit loss expense in the first nine months primarily related to the collection risk from several biotech receivable balances in the first quarter.